Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Reference library
Home/Knowledge Hub/EU GMP/EudraLex Vol 4, Part I, Chapter 9
Full text of a document published by European Commission, taken from the publisher's official file on 9 Nov 2026. The wording is as published; the cover page, contents list and page headers are left out and the layout is ours. The publisher's version is authoritative. Added 09 Nov 2026
EU GMP · EU GMP Guide (EudraLex Volume 4)

EU GMP Chapter 9: Self Inspection

EU GMP Guide (EudraLex Volume 4) from European Commission. Full text: 135 words in 1 section, about 1 min to read.

EudraLex Vol 4, Part I, Chapter 9 1 section 135 words ~1 min read Original GMP Guide text (no revision date) In force Official source ↗ Download Word (.docx) Share

Principle

Self inspections should be conducted in order to monitor the implementation and compliance with Good Manufacturing Practice principles and to propose necessary corrective measures.

9.1 Personnel matters, premises, equipment, documentation, production, quality control, distribution of the medicinal products, arrangements for dealing with complaints and recalls, and self inspection, should be examined at intervals following a pre-arranged programme in order to verify their conformity with the principles of Quality Assurance.

9.2 Self inspections should be conducted in an independent and detailed way by designated competent person(s) from the company. Independent audits by external experts may also be useful.

9.3 All self inspections should be recorded. Reports should contain all the observations made during the inspections and, where applicable, proposals for corrective measures. Statements on the actions subsequently taken should also be recorded.

Source and reuse

EU GMP Chapter 9: Self Inspection. European Commission, Original GMP Guide text (no revision date). Official version: https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en (copied 9 Nov 2026). © European Union. Reused under the European Commission's reuse policy (Decision 2011/833/EU, CC BY 4.0). Priya Life Science changed the formatting only. Reuse terms.